SCHEMBL1819086

SCHEMBL1819086

CCOC(=O)C(=O)N1CCCCC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.61
GAA P10253 1/20 0.57
L3MBTL1 Q9Y468 5/20 0.49
PKM P14618 1/20 0.48
HPGD P15428 5/20 0.45
ALDH1A1 P00352 6/20 0.44
KDM4E B2RXH2 2/20 0.44
TSHR P16473 3/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
THRB P10828 1/20 0.42
ATM Q13315 1/20 0.42
LMNA P02545 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6331933 0.98 MAPT (0.62) MAPTGAAL3MBTL1PKMHPGD
SCHEMBL12496523 0.89 MAPT (0.67) MAPTGAAL3MBTL1PKMALDH1A1
SCHEMBL18828621 0.82 MAPT (0.47) MAPTGAAL3MBTL1PKMHPGD
SCHEMBL13601717 0.82 MAPT (0.59) MAPTGAAL3MBTL1PKMALDH1A1
SCHEMBL14477874 0.82 MAPT (0.59) MAPTGAAL3MBTL1PKMALDH1A1
SCHEMBL28060009 0.81 ALDH1A1 (0.53) MAPTL3MBTL1HPGDALDH1A1TSHR
SCHEMBL8710504 0.80 ALDH1A1 (0.61) MAPTGAAL3MBTL1ALDH1A1KDM4E
SCHEMBL11402027 0.80 ALDH1A1 (0.61) MAPTGAAL3MBTL1ALDH1A1KDM4E
SCHEMBL675456 0.80 ALDH1A1 (0.61) MAPTGAAL3MBTL1ALDH1A1KDM4E
SCHEMBL21138457 0.80 ALDH1A1 (0.61) MAPTGAAL3MBTL1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487494-B2 Cyclic hydrocarbon compounds for the treatment of diseases LEO PHARMA A/S (DK) 2016-11-08 US claimed
US-20100317582-A1 NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2010-12-16 US claimed
EP-2234961-A2 NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2010-10-06 EP claimed
WO-2009065406-A2 NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2009-05-28 WO claimed
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics 2023-10-26 US disclosed
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics 2023-10-26 US disclosed
EP-3681504-B1 METHODS OF DETECTION USING X-RAY FLUORESCENCE ICAGEN INC (US) 2023-08-23 EP disclosed
US-11573224-B2 Methods of detection using X-ray fluorescence ICAGEN, LLC (US) 2023-02-07 US disclosed
US-11446398-B2 Regulated biocircuit systems OBSIDIAN THERAPEUTICS, INC. (US) 2022-09-20 US disclosed
US-11390589-B2 Herbicidally active substituted phenylpyrimidines BAYER AKTIENGESELLSCHAFT (DE) 2022-07-19 US disclosed
US-20210317089-A1 HERBICIDALLY ACTIVE SUBSTITUTED PHENYLPYRIMIDINES BAYER AKTIENGESELLSCHAFT (DE) 2021-10-14 US disclosed
US-20210254056-A1 IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS CAMP4 THERAPEUTICS CORPORATION 2021-08-19 US disclosed
WO-2007026959-A2 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 WO disclosed
EP-0469889-B1 (p-Carbonylaminophenyl)-sulphonyl-nitromethane derivatives ZENECA LTD (GB) 1996-01-17 EP disclosed
US-5189031-A Inhibitor of enzyme aldose reductase, useful in the treatment of certain peripheral effects of diabetes and galactosemia IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-02-23 US disclosed
EP-0338386-B1 NEW METHOD OF PREPARATION OF OXALIC ACID ESTERS AND AMIDES Enichem Anic S.r.l. (IT) 1992-09-02 EP disclosed
US-5110808-A Aldose reductase inhibitors; peripheral effects of diabetes and galactosemia IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) 1992-05-05 US disclosed
EP-0469889-A1 (p-Carbonylaminophenyl)-sulphonyl-nitromethane derivatives ZENECA LIMITED (GB) 1992-02-05 EP disclosed
US-4981963-A Method of preparation of oxalic acid esters and amides ENICHEM ANIC S.P.A. (IT) 1991-01-01 US disclosed
EP-0338386-A1 New method of preparation of oxalic acid esters and amides Enichem Anic S.r.l. (IT) 1989-10-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317089-A1 HERBICIDALLY ACTIVE SUBSTITUTED PHENYLPYRIMIDINES DDT, DPYD, GSTP1 MAPT 3392/4885GAA 108/4885L3MBTL1 1159/4885
US-20100317582-A1 NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES ARNT, AHR, CYP27A1 MAPT 3979/4885GAA 1308/4885L3MBTL1 4065/4885
US-11390589-B2 Herbicidally active substituted phenylpyrimidines DDT, DPYD, GSTP1 MAPT 3392/4885GAA 108/4885L3MBTL1 1159/4885
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS SREBF1, SREBF2, NR1H3 MAPT 4392/4885GAA 2366/4885L3MBTL1 3281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.